FDA Approves Myriad Genetics BRCA CDx with Pfizer’s Metastic Breast Cancer Drug

The US Food and Drug Administration has approved Myriad Genetics’ BRACAnalysis CDx for determining which HER2-negative, metastatic breast cancer patients have inherited BRCA1 and BRCA2 genetic mutations and therefore may benefit from treatment with Pfizer’s Talzenna (talazoparib).  The study showed that Talzenna-treated patients had a median progression-free survival of 8.6 months compared to 5.6 months for those receiving their physician’s choice of treatment with capecitabine, eribulin, gemcitabine, or vinorelbine.

Source: https://www.genomeweb.com/regulatory-news/fda-approves-myriad-genetics-brca-cdx-pfizers-metastatic-breast-cancer-drug